As of November 6, 2026, Oric Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: ORIC); its largest reported holder is Nextech Crossover I GP S.a. r.l., with 8.4% on Schedule 13G/A of August 14, 2025, then Viking Global (7.8%) (Schedule 13G/A, August 14, 2025).
Is this your company?
About to sign with, pay or invest in Oric Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Oric Pharmaceuticals, Inc. a real, registered company?
- Oric Pharmaceuticals, Inc. files with the SEC under CIK 1796280 (its SEC filings).
- Its shares are listed under the ticker ORIC on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in South San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Oric Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names T. Rowe Price (filed 2026-05-15).
Who are Oric Pharmaceuticals, Inc.'s owners and officers?
Oric Pharmaceuticals, Inc.: incorporated in Delaware; business address in South San Francisco, California; industry Pharmaceutical Preparations (Schedule 13G, 2026-05-15).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-06-06)
- : Executive Officer (Form D, 2025-06-06)
- : Executive Officer (Form D, 2025-06-06)
- : Director (Form D, 2025-06-06)
- : Director (Form D, 2025-06-06)
- : Director (Form D, 2025-06-06)
- : Director (Form D, 2025-06-06)
- : Director (Form D, 2025-06-06)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-05-15 | T. Rowe Price Associates, Inc. | 5.4% |
| Schedule 13G/A, 2026-05-15 | Point72 Asset Management, L.P. | 0% |
| Schedule 13G/A, 2026-05-15 | Venrock Healthcare Capital Partners Iii, L.P. | 4.2% |
| Schedule 13G/A, 2026-05-15 | Viking Global Investors LP | 7.8% |
| Schedule 13G/A, 2026-05-12 | Pfizer Inc. (Irs Identification No.: 13-5315170) | 3.3% |
| Schedule 13G/A, 2026-02-17 | Venrock Healthcare Capital Partners Iii, L.P. | 5.8% |
| Schedule 13G, 2026-01-21 | Blackrock, Inc. | 5.6% |
| Schedule 13G/A, 2025-11-17 | David V Goeddel | 3.7% |
| Schedule 13G/A, 2025-11-13 | Alkeon Capital Management LLC | 4.6% |
| Schedule 13G/A, 2025-08-14 | Nextech Crossover I Gp S.A. R.L. | 8.4% |
| Schedule 13D/A, 2025-08-14 | Sr One Capital Management, LLC | 4.75% |
| Schedule 13G/A, 2025-08-14 | Viking Global Investors LP | 9.99% |
Questions about who owns Oric Pharmaceuticals, Inc.
Who owns Oric Pharmaceuticals, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Oric Pharmaceuticals, Inc.: Nextech Crossover I Gp S.A. R.L. (8.4%, Schedule 13G/A, filed 2025-08-14), Viking Global Investors LP (7.8%, Schedule 13G/A, filed 2026-05-15), Blackrock, Inc. (5.6%, Schedule 13G, filed 2026-01-21) and T. Rowe Price Associates, Inc. (5.4%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Oric Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Oric Pharmaceuticals, Inc. on this page are Nextech Crossover I Gp S.A. R.L. (8.4%), Viking Global Investors LP (7.8%) and Blackrock, Inc. (5.6%).
When did Nextech Crossover I Gp S.A. R.L. buy into Oric Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Nextech Crossover I Gp S.A. R.L. on this page is the Schedule 13G/A, filed 2025-08-14, reporting 8.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Oric Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Oric Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Oric Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Oric Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 581,711 shares (0.56% of shares outstanding) (Form 4, 2025-12-17).
- , a director: 241,772 shares (0.23% of shares outstanding), 38,300 held directly and 203,472 indirectly (Form 4, 2026-10-02).
- , a director: 84,200 shares (0.08% of shares outstanding) (Form 4, 2025-12-09).
- , the chief financial officer: 69,828 shares (0.07% of shares outstanding) (Form 4, 2026-10-21).
- , the chief medical officer: 68,149 shares (0.07% of shares outstanding) (Form 4, 2025-12-17).
Shares outstanding: 103,652,656 as of 2026-07-27, from the company's latest SEC cover page.
How much has Oric Pharmaceuticals, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-06-06 | $125M | $125M |
| Form D, 2024-01-30 | $125M | $125M |
| Form D, 2023-07-05 | $85M | $85M |
Keep reading
More on Oric Pharmaceuticals, Inc. and the records around it.
Oric Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Form D filing Jun 2025
Companies that share a holder
- Alkeon Capital Management LLC also filed stake reports on 1 other company: Hinge Health, Inc. (Feb 2026)
- Nextech Crossover I GP S.a. r.l. also filed stake reports on 2 other companies: Tango Therapeutics, Inc. (Aug 2026)
- Pfizer Inc. (IRS Identification No.: 13-5315170) also filed stake reports on 4 other companies: TREX BIO, INC. (Oct 2026), Allogene Therapeutics, Inc. (Feb 2026), NEXTCURE, INC. (Feb 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/oric-pharmaceuticals